D68.312 — Antiphospholipid antibody with hemorrhagic disorder
Is D68.312 billable?
Yes — D68.312 is billable for FY2027. D68.312 is a valid, billable ICD-10-CM code at the highest level of specificity in its branch. D68.312 may be submitted for encounters from October 1, 2026 through September 30, 2027.
D68.312 at a glance
| Code | D68.312 |
|---|---|
| Description | Antiphospholipid antibody with hemorrhagic disorder |
| Billable | Yes |
| Code set | ICD-10-CM FY2027 |
| Valid for encounters | October 1, 2026 – September 30, 2027 |
Which MS-DRGs does D68.312 group to?
D68.312 sits in MDC 16 and helps define the logic of 3 MS-DRGs (version 44, FY2027). Which one a stay actually groups to also depends on procedures and secondary diagnoses.
- 814Reticuloendothelial and Immunity Disorders with MCCmedical
- 815Reticuloendothelial and Immunity Disorders with CCmedical
- 816Reticuloendothelial and Immunity Disorders without CC/MCCmedical
As a secondary diagnosis, D68.312 is a complication or comorbidity (CC), which can move a stay into a higher-paying DRG.
How is D68.312 listed in the Alphabetic Index?
These are the routes through the Alphabetic Index that lead to D68.312. They show the wording a clinician may have documented, which often differs from the Tabular description.
- Antiphospholipid › antibody › with hemorrhagic disorder
- Antibody › anticardiolipin › with › hemorrhagic disorder
- Antibody › antiphosphatidylglycerol › with › hemorrhagic disorder
- Antibody › antiphosphatidylinositol › with › hemorrhagic disorder
- Antibody › antiphosphatidylserine › with › hemorrhagic disorder
- Antibody › antiphospholipid › with › hemorrhagic disorder
- Lupus › anticoagulant › with › hemorrhagic disorder
- Lupus › erythematosus › systemic › inhibitor › with › hemorrhagic disorder
Excludes1 — never code together
The conditions below can never be reported together with D68.312 on the same claim. An Excludes1 note means the two conditions cannot occur in the same patient, so reporting both is a coding error.
Excludes2 — not included here
The conditions below are not part of D68.312, but a patient may have both at the same time. When documentation supports it, D68.312 and the excluded code may both be reported.
Inclusion terms
Alternative wording in documentation that is classified to D68.312.
- Lupus anticoagulant (LAC) with hemorrhagic disorder
- Systemic lupus erythematosus [SLE] inhibitor with hemorrhagic disorder
Excludes1 — never code together — inherited from D68
The conditions below can never be reported together with D68.312 on the same claim. An Excludes1 note means the two conditions cannot occur in the same patient, so reporting both is a coding error.
- abnormal coagulation profile NOS (R79.1)
Excludes2 — not included here — inherited from Chapter 3
The conditions below are not part of D68.312, but a patient may have both at the same time. When documentation supports it, D68.312 and the excluded code may both be reported.
- autoimmune disease (systemic) NOS (M35.9)
- certain conditions originating in the perinatal period (P00-P96)
- complications of pregnancy, childbirth and the puerperium (O00-O9A)
- congenital malformations, deformations and chromosomal abnormalities (Q00-Q99)
- endocrine, nutritional and metabolic diseases (E00-E88)
- human immunodeficiency virus [HIV] disease (B20)
- injury, poisoning and certain other consequences of external causes (S00-T88)
- neoplasms (C00-D49)
- symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified (R00-R94)
Excludes2 — not included here — inherited from D68
The conditions below are not part of D68.312, but a patient may have both at the same time. When documentation supports it, D68.312 and the excluded code may both be reported.
How long has D68.312 existed?
D68.312 has been in ICD-10-CM since at least FY2016, the earliest fiscal year on record here.
Derived from the official order files for FY2016–FY2026. FY2017 and FY2020 publish no order file, so those years are not covered.